| Volta Medical Group | |
|
9415 Mission Blvd Ste P Jurupa Valley CA 92509-2600 | |
| (833) 865-8263 | |
| Not Available |
| Full Name | Volta Medical Group |
|---|---|
| Speciality | Clinic/Center |
| Location | 9415 Mission Blvd Ste P, Jurupa Valley, California |
| Authorized Official Name and Position | Maxwell Setsoafia (CEO) |
| Authorized Official Contact | 3103084550 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Volta Medical Group 9415 Mission Blvd Ste P Jurupa Valley CA 92509-2600 Ph: (833) 865-8263 | Volta Medical Group 9415 Mission Blvd Ste P Jurupa Valley CA 92509-2600 Ph: (833) 865-8263 |
| NPI Number | 1245972306 |
|---|---|
| Provider Enumeration Date | 04/10/2022 |
| Last Update Date | 05/13/2023 |
| Medicare PECOS PAC ID | 0749655033 |
|---|---|
| Medicare Enrollment ID | O20230419002179 |
News Archive
Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
ZOLL Medical Corporation announced today that in a "Best of the Best" presentation at the American Heart Association Resuscitation Science Symposium in Orlando Florida, Daniel P. Davis, M.D., presented research from the University of California Resuscitation Research Center that shows a major improvement in patient outcome after cardiac arrest.
The field of cell therapy, which aims to form new cells in the body in order to cure disease, has taken another important step in the development towards new treatments.
Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.
› Verified 2 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1245972306 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 261QP2300X | Clinic/center - Primary Care | (* (Not Available)) | Primary |
| Provider Name | Michele Teresa Vargas |
|---|---|
| Provider Type | Practitioner - Emergency Medicine |
| Provider Identifiers | NPI Number: 1306873583 PECOS PAC ID: 7113822065 Enrollment ID: I20031203000730 |
News Archive
Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
ZOLL Medical Corporation announced today that in a "Best of the Best" presentation at the American Heart Association Resuscitation Science Symposium in Orlando Florida, Daniel P. Davis, M.D., presented research from the University of California Resuscitation Research Center that shows a major improvement in patient outcome after cardiac arrest.
The field of cell therapy, which aims to form new cells in the body in order to cure disease, has taken another important step in the development towards new treatments.
Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.
› Verified 2 days ago
News Archive
Afatinib has been approved in Germany since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).
ZOLL Medical Corporation announced today that in a "Best of the Best" presentation at the American Heart Association Resuscitation Science Symposium in Orlando Florida, Daniel P. Davis, M.D., presented research from the University of California Resuscitation Research Center that shows a major improvement in patient outcome after cardiac arrest.
The field of cell therapy, which aims to form new cells in the body in order to cure disease, has taken another important step in the development towards new treatments.
Aeolus Pharmaceuticals, Inc. announced today that it has completed a $1.0 million financing with two existing institutional shareholders, both of which are affiliates of Xmark Opportunity Partners, LLC.
› Verified 2 days ago
Inland Empire Medical Group, Inc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 10250 Country Club Dr Ste A, Jurupa Valley, CA 91752 Phone: 952-332-6360 Fax: 951-332-0313 | |
Troth Street Elementary Clinic Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5565 Troth St, Jurupa Valley, CA 91752 Phone: 951-710-3987 | |
Jurupa Valley Community Health Center - Troth Elementary Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 5565 Troth St, Jurupa Valley, CA 91752 Phone: 951-617-1261 |